RET (G810R)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.G810R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Selpercatinib | 91.0% | 8.9% | 96.72 |
| 2 | Tivozanib | 90.5% | 9.5% | 92.42 |
| 3 | Pralsetinib | 88.8% | 11.2% | 93.43 |
| 4 | Sorafenib | 72.4% | 27.6% | 96.72 |
| 5 | Ripretinib | 60.4% | 39.6% | 92.95 |
| 6 | Apatinib | 39.7% | 60.3% | 97.73 |
| 7 | Repotrectinib | 39.3% | 60.7% | 84.21 |
| 8 | Fedratinib | 26.5% | 73.5% | 96.21 |
| 9 | Tenalisib | 25.5% | 74.5% | 97.98 |
| 10 | Capivasertib | 24.6% | 75.4% | 96.48 |
| 11 | Alpelisib | 17.9% | 82.1% | 97.22 |
| 12 | Entrectinib | 17.4% | 82.6% | 93.69 |
| 13 | Selumetinib | 9.7% | 90.3% | 100.00 |
| 14 | Umbralisib | 6.8% | 93.2% | 98.74 |
| 15 | Futibatinib | 4.4% | 95.6% | 98.48 |
| 16 | Erdafitinib | 4.3% | 95.7% | 95.71 |
| 17 | Upadacitinib | 3.8% | 96.2% | 97.98 |
| 18 | Leniolisib | 3.4% | 96.6% | 100.00 |
| 19 | Canertinib | 3.3% | 96.8% | 96.49 |
| 20 | Rabusertib | 2.8% | 97.2% | 98.74 |
| 21 | Vandetanib | 2.5% | 97.5% | 95.74 |
| 22 | Defactinib | 2.4% | 97.6% | 92.68 |
| 23 | Infigratinib | 2.2% | 97.8% | 98.24 |
| 24 | Abemaciclib | 2.0% | 98.0% | 91.48 |
| 25 | Idelalisib | 1.9% | 98.1% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Selpercatinib | 91.0% | 100.0% | -9.0% |
| Tivozanib | 90.5% | 99.7% | -9.2% |
| Pralsetinib | 88.8% | 100.0% | -11.2% |
| Sorafenib | 72.4% | 94.0% | -21.5% |
| Ripretinib | 60.4% | — | — |
| Apatinib | 39.7% | — | — |
| Repotrectinib | 39.3% | — | — |
| Fedratinib | 26.5% | 99.9% | -73.4% |
| Tenalisib | 25.5% | 98.5% | -73.0% |
| Capivasertib | 24.6% | — | — |
| Alpelisib | 17.9% | 99.6% | -81.7% |
| Entrectinib | 17.4% | 99.6% | -82.2% |
| Selumetinib | 9.7% | — | — |
| Umbralisib | 6.8% | — | — |
| Futibatinib | 4.4% | 97.7% | -93.3% |
| Erdafitinib | 4.3% | 94.7% | -90.3% |
| Upadacitinib | 3.8% | — | — |
| Leniolisib | 3.4% | — | — |
| Canertinib | 3.3% | — | — |
| Rabusertib | 2.8% | — | — |
| Vandetanib | 2.5% | 98.6% | -96.0% |
| Defactinib | 2.4% | — | — |
| Infigratinib | 2.2% | — | — |
| Abemaciclib | 2.0% | — | — |
| Idelalisib | 1.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms